Treating residual cardiovascular risk: will lipoprotein-associated phospholipase A2 inhibition live up to its promise?
Koenig
Wolfgang
W
D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase / Q000037:antagonists & inhibitors* / Q000097:blood / Q000187:drug effects; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D000069059:Atorvastatin; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000201:enzymology; D006538:Heptanoic Acids / Q000627:therapeutic use; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D011758:Pyrroles / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D000924:Anticholesteremic Agents; D006538:Heptanoic Acids; D011758:Pyrroles; D000069059:Atorvastatin; D043203:1-Alkyl-2-acetylglycerophosphocholine Esterase